October 1986 in “Inpharma” Spironolactone helps reduce hair growth in women with hirsutism but may cause menstrual irregularities.
October 2025 in “Influenza and Other Respiratory Viruses” Certain alkaloids could help create new coronavirus drugs.
49 citations
,
October 1994 in “Annals of Oncology” Minoxidil not effective in preventing chemotherapy-induced hair loss.
October 2007 in “Obstetrical & Gynecological Survey” Low-dose methotrexate, combined with surgical and local treatments, effectively treats severe vulvovaginal lichen planus.
9 citations
,
October 2020 in “Journal of The American Academy of Dermatology” Low-dose oral minoxidil is an effective and well-tolerated treatment for hair growth in alopecia patients.
51 citations
,
July 2003 in “Annals of the Rheumatic Diseases” Co-trimoxazole may help treat autoimmune diseases.
January 2002 in “Analecta malacitana: Revista de la Sección de Filología de la Facultad de Filosofía y Letras” Minoxidil is a popular hair growth treatment, but how it works isn't fully understood.
14 citations
,
May 2018 in “Journal of the American Academy of Dermatology” Platelet-rich plasma might be a new way to treat lichen planopilaris.
2 citations
,
October 2020 in “Más dermatología” Choose between topical and oral minoxidil for hair growth based on personal tolerance and side effects.
October 2022 in “Journal of experimental and clinical medicine” Repurposing existing drugs for COVID-19 shows promise but requires more research to confirm effectiveness.
15 citations
,
January 2000 in “Dermatology” Minoxidil use may cause skin pigmentation loss.
12 citations
,
March 2016 in “Life Sciences” The new chemotherapy combination of WP 631 and Epothilone B shows enhanced effectiveness against ovarian cancer but requires more research on its safety.
50 citations
,
July 2021 in “Nature Communications” The drug enzalutamide may reduce the ability of the virus causing COVID-19 to enter lung cells.
April 2025 in “Research Square (Research Square)” Minoxidil microinfusion lowered diastolic blood pressure in patients.
1 citations
,
January 2020 in “Surgical & Cosmetic Dermatology” Combining oral minoxidil with JAK inhibitors helps regrow hair in severe alopecia areata cases.
3 citations
,
November 2024 in “Clinical Research” Deuruxolitinib is FDA-approved for treating severe alopecia areata.
36 citations
,
June 1990 in “Archives of Dermatology” Using minoxidil and anthralin together can improve hair regrowth in severe alopecia areata patients who didn't respond to individual treatments.
1 citations
,
May 2022 in “Revista Contemporânea” Combining two treatments for hair loss works better than using just one.
6 citations
,
November 2022 in “Journal of Tissue Engineering and Regenerative Medicine” Zebularine improved skin structure but delayed wound healing in diabetic mice.
September 2022 in “Research Square (Research Square)” 5% topical minoxidil improves hair density and quality in monilethrix patients.
1 citations
,
June 2001 in “Annals of Internal Medicine” Troglitazone increases subcutaneous fat in lipodystrophy patients.
January 2025 in “Skin Appendage Disorders” Low-dose oral minoxidil does not significantly change alcohol consumption.
3 citations
,
September 2021 in “JAAD case reports” Denosumab, a bone loss treatment, may cause hair loss and skin reactions due to immune system effects.
June 2025 in “Samarra Journal of Pure and Applied Science” A new method accurately measures minoxidil in tablets.
18 citations
,
September 2021 in “Colloids and surfaces. B, Biointerfaces” Nanoparticles can effectively deliver spironolactone to hair follicles for treating alopecia and acne.
January 2014 in “Международный журнал прикладных и фундаментальных исследований” Zinc affects hair growth and may be linked to hair loss.
5 citations
,
May 2023 in “Clinical Rheumatology” Tofacitinib helped regrow hair in a lupus patient with alopecia.
September 2025 in “Journal of the American Academy of Dermatology” Low-dose oral minoxidil may be a promising alternative to topical minoxidil for hair loss.
3 citations
,
March 2017 in “Regulatory toxicology and pharmacology” Aleglitazar and its major metabolite are safe enough to proceed to Phase 3 clinical trials.
2 citations
,
February 2020 in “Rivista Urologia” Both terazosin and baclofen effectively reduce pain in young men with chronic testicular pain, with no difference in their effectiveness.